Photo courtesy of LINK-J
Veneno Technologies presented at “TOKYO Biotech Day 2026 by TIB CATAPULT/LINK-BioBAY TOKYO” on October 5, 2026, as a startup selected for the second cohort of The Masterclass Program by BioLabs.
CEO Kuno introduced Veneno’s approach to discovering medicines from venom-derived peptides. The company’s proprietary Veneno Suite™ platform combines AI with data from its own lab to identify peptide candidates and evaluate their effects on target molecules. The pitch also outlined how Veneno plans to advance its drug discovery programs and expand internationally.
A certificate of completion was also presented to Veneno Technologies at the event.
Related link:
TOKYO Biotech Day 2026 by TIB CATAPULT/LINK-BioBAY TOKYO Held on October 5 (10/5)
